

12 June, 2026

National Stock Exchange of India Limited

Exchange Plaza, 5th Floor, C-1,
Block G, Bandra Kurla Complex,
Bandra (E), Mumbai 400051

NSE SYMBOL: INVICTA

ISIN: INE0XJ501010

Subject: Updation regarding our previous Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”) about Incorporation of Step-Down Subsidiary LLP

Dear Sir/Madam,

In continuance with our previous intimation dated 01 June, 2026 and Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”), read with Schedule III thereto and SEBI Master Circulars issued from time to time, we informed you that the Porteus Medical LLP a subsidiary LLP of the Company, has incorporated a Limited Liability Partnership namely Porteus Pathogenius LLP and Consequent to the above incorporation, Porteus Pathogenius LLP has become a Step-Down Subsidiary of the Company.

We hereby inform you that the Initial LLP agreement of Porteus Pathogenius LLP dated 12 June, 2026 has been executed today.

The details as required under Regulation 30 of the SEBI Listing Regulations are enclosed herewith as Annexure – A.

This is for your information and record.

Thanking you,

Yours Faithfully,

For Invicta Diagnostic Limited

Sanket Vinod Jain
Chairman and Non-Executive Director
DIN: 08299039
Place: Mumbai

Annexure A- Disclosure pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Sr. No.	Particulars	Details
1	Name of the target entity, details in brief such as size, turnover etc.	Porteus Pathogenius LLP (“LLP”), a newly incorporated LLP. LLPIN: ACY-7934. Initial Total Capital Contribution: Rs. 1,00,000/- Initial capital contribution of Rs. 51,000/- by Porteus Medical LLP towards its partnership interest of 51% in the LLP. Since the LLP has been newly incorporated, turnover is Nil.
2	Whether the acquisition would fall within related party transaction(s) and whether the promoter /promoter group / group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at arm's length	The transaction does not fall within the ambit of a related party transaction. Porteus Pathogenius LLP has been incorporated as a new entity by Porteus Medical LLP, a subsidiary of the Company. Except to the extent of indirect control through Porteus Medical LLP, neither the promoter/promoter group nor any group company has any direct interest in Porteus Pathogenius LLP.
3	Industry to which the entity being acquired belongs	Healthcare / Diagnostics / Pathology Services
4	Objects and impact of acquisition	The LLP has been incorporated to undertake the business of diagnostics, pathology, healthcare services, laboratory services etc. and to expand the business operations of the group.
5	Brief details of any governmental or regulatory approvals required	No specific governmental or regulatory approvals are required for incorporation, except such approvals, registrations or licenses as may be required in the ordinary course of business.
6	Indicative time period for completion of acquisition	Completed. Initial LLP Agreement has been executed on 12 June, 2026.
7	Consideration	Initial capital contribution of Rs. 51,000/- by Porteus Medical LLP towards its partnership interest of 51% in the LLP.
8	Cost of acquisition and/or the price at which the shares are acquired	Rs. 51,000/- for 51% partnership interest in LLP at par.
9	Percentage of shareholding/control acquired and/or number of shares acquired	Porteus Medical LLP holds 51% partnership interest/control in Porteus Pathogenius LLP. Consequently, Porteus Pathogenius LLP has become a Step-Down Subsidiary of the Company.
10	Brief background about the entity acquired	Porteus Pathogenius LLP is incorporated under the Limited Liability Partnership Act, 2008 and is yet to commence business operations. The LLP has been incorporated and the initial LLP Agreement is executed by the partners on 12 June, 2026.